Eocene Ltd (EOCN)

Currency in USD
3.630
+0.010(+0.28%)
Closed·
3.5100.000(0.00%)
·
EOCN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
3.5603.800
52 wk Range
3.26713.200
Key Statistics
Prev. Close
3.62
Open
3.62
Day's Range
3.56-3.8
52 wk Range
3.267-13.2
Volume
3.45K
Average Volume (3m)
60.94K
1-Year Change
-67.1196%
Book Value / Share
13.26
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
EOCN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
0.000
Downside
-100.00%
Members' Sentiments
Bearish
Bullish
ProTips
Significant return over the last week

Eocene Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell

Analyst Ratings

0 Buy
1 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 0.000

Earnings

Latest Release
Jul 30, 2026
EPS / Forecast
-2,86 / -3,12
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

EOCN Income Statement

Compare EOCN to Peers and Sector

Metrics to compare
EOCN
Peers
Sector
Relationship
P/E Ratio
−0.3x−2.1x−0.4x
PEG Ratio
−0.010.000.00
Price/Book
0.3x1.8x2.6x
Price / LTM Sales
-0.0x3.0x
Upside (Analyst Target)
-1,036.8%57.0%
Fair Value Upside
Unlock−1.7%8.0%Unlock

Eocene Ltd. a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through the ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company is developing MyBiotics, which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform and Tissue Dynamics to develop a novel human chronic cardiac fibrosis model. Eocene Ltd. was formerly known as Galmed Pharmaceuticals Ltd. and changed its name to Eocene Ltd. in September 2026. Eocene Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
246,000,02%890,52
Other Institutional Investors
42,44K4,24%153,65K
Public Companies & Retail Investors
958,70K95,74%3,47M
Total
1M100,00%3,63M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Heights Capital Management, Inc.2,16%21 66778
Citadel Advisors LLC1,08%10 85639

FAQ

What Is the EoCene (EOCN) Stock Price Today?

The EoCene stock price today is 3,630 USD.

What Stock Exchange Does EoCene Trade On?

EoCene is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for EoCene?

The stock symbol for EoCene is "EOCN."

What Is the EoCene Market Cap?

As of today, EoCene market cap is 3,780M USD.

What Is EoCene's Earnings Per Share (TTM)?

The EoCene EPS (TTM) is -14,106.

When Is the Next EoCene Earnings Date?

EoCene will release its next earnings report on Nov 25, 2026.

From a Technical Analysis Perspective, Is EOCN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has EoCene Stock Split?

EoCene has split 3 times.

How Many Employees Does EoCene Have?

EoCene has 5 employees.

What is the current trading status of EoCene (EOCN)?

As of Sep 25, 2026, EoCene (EOCN) is trading at a price of 3,630 USD, with a previous close of 3,620 USD. The stock has fluctuated within a day range of 3,560 USD to 3,800 USD, while its 52-week range spans from 3,267 USD to 13,200 USD.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.